[HTML][HTML] Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non–small-cell lung cancer
EB Garon, RJ Pietras, RS Finn, N Kamranpour… - Journal of Thoracic …, 2013 - Elsevier
Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …
[HTML][HTML] Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small cell lung cancer
EB Garon, RJ Pietras, RS Finn… - Journal of thoracic …, 2013 - ncbi.nlm.nih.gov
Methods We evaluated 54 NSCLC cell lines for growth inhibition with EGFR inhibitors,
antiestrogen treatment or the combination. Each line was evaluated for baseline ER …
antiestrogen treatment or the combination. Each line was evaluated for baseline ER …
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
EB Garon, RJ Pietras, RS Finn… - Journal of Thoracic …, 2013 - hero.epa.gov
INTRODUCTION: Estrogen receptor (ER) signaling and its interaction with epidermal growth
factor receptor (EGFR) is a potential therapeutic target in non-small-cell lung cancer …
factor receptor (EGFR) is a potential therapeutic target in non-small-cell lung cancer …
[PDF][PDF] Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
EB Garon, RJ Pietras, RS Finn, N Kamranpour… - Journal of Thoracic …, 2013 - core.ac.uk
Methods: We evaluated 54 NSCLC cell lines for growth inhibition with EGFR inhibitors,
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
EB Garon, RJ Pietras, RS Finn… - Journal of thoracic …, 2013 - pubmed.ncbi.nlm.nih.gov
Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non-small-cell lung cancer (NSCLC). To …
receptor (EGFR) is a potential therapeutic target in non-small-cell lung cancer (NSCLC). To …
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
EB Garon, RJ Pietras, RS Finn… - Journal of Thoracic …, 2013 - europepmc.org
Methods We evaluated 54 NSCLC cell lines for growth inhibition with EGFR inhibitors,
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …
[HTML][HTML] Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
EB Garon, RJ Pietras, RS Finn, N Kamranpour… - Journal of Thoracic …, 2013 - jto.org
Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …
[引用][C] Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
EB Garon, RJ Pietras, RS Finn, N Kamranpour… - Journal of Thoracic …, 2013 - cir.nii.ac.jp
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor
Receptor Inhibitors in Human Non–Small-Cell Lung Cancer | CiNii Research CiNii 国立情報学 …
Receptor Inhibitors in Human Non–Small-Cell Lung Cancer | CiNii Research CiNii 国立情報学 …
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
EB Garon, RJ Pietras, RS Finn… - Journal of Thoracic …, 2013 - europepmc.org
Methods We evaluated 54 NSCLC cell lines for growth inhibition with EGFR inhibitors,
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …
antiestrogen treatment, or the combination. Each line was evaluated for baseline ER …